Posted by Michael Wonder on 23 Nov 2016
NICE publishes final guidance on the use of nivolumab for RCC
23 November 2016 - NICE has published its third final appraisal determination for nivolumab for 2016.
Nivolumab is recommended, within its marketing authorisation, as an option for previously treated advanced renal cell carcinoma in adults, when the company provides nivolumab with the discount agreed in the patient access scheme.
